{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In what could prove to be one of the first major drugs to emerge from the human genome project, a chemical that singles out a specific gene thought to increase the risk of heart attacks has shown promising results in a preliminary test. Last year DeCode Genetics, a gene-finding company in Reykjavik, Iceland, discovered among Icelanders a variant gene that doubled the risk of heart attack and stroke. Because a drug that inhibited the gene had been developed, although for a different purpose, DeCode was able to begin a clinical trial almost immediately.", "headline": {"main": "Drug in Test Acts on Gene Tied to Heart"}, "abstract": "Chemical that singles out specific gene thought to increase risk of heart attacks shows promising results in preliminary test, in what could prove to be one of first major drugs to emerge from human genome project; DeCode Genetics, gene-finding company in Reykjavik, Iceland, discovered among Icelanders a variant gene that doubled risk of heart attack and stroke; drug that inhibited the gene had been developed, although for different purpose, and DeCode was able to begin clinical trial almost immediately (M)", "print_page": "15", "word_count": 768, "_id": "4fd284b58eb7c8105d853dff", "snippet": "A chemical that singles out a gene thought to increase the risk of heart attacks has shown promising results in a preliminary test.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/05/11/health/11heart.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "ICELAND"}, {"name": "organizations", "value": "AMERICAN MEDICAL ASSN"}, {"name": "organizations", "value": "DECODE GENETICS"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "HUMAN GENOME PROJECT"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Nicholas", "rank": 1, "lastname": "WADE"}], "original": "By NICHOLAS WADE"}, "document_type": "article", "pub_date": "2005-05-11T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Is it a drug in search of a disease, or simply an affliction in need of better publicity? One of the afflicted is Peter Pagan. After suffering a severe brain injury in a fall, he would burst into tears at the slightest provocation, even when he was not feeling sad.", "headline": {"main": "Marketing a Disease, and Also a Drug to Treat It"}, "abstract": "Avanir Pharmaceuticals is testing Neurodex, drug to treat uncontrollable laughing or crying caused by various neurological diseases or injuries; critics say condition, in people who are typically fighting much more serious health problems, does not warrant drug therapy; Avanir has recruited neurologists and psychiatrists as scientific advisers and is trying to prime market by elevating ill-defined group of symptoms into condition under name psuedobulbar affect, or PBA, in hopes of establishing awareness of it among doctors and patients; chief executive Gerald J Yakatan comments; photos (M)", "print_page": "1", "word_count": 1776, "_id": "4fd25e008eb7c8105d80d088", "snippet": "Is it a drug in search of a disease, or simply an affliction in need of better publicity?    One of the afflicted is Peter Pagan. After suffering a severe brain injury in a fall, he would burst into tears at the slightest provocation, even when he...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9400E4D61530F93AA35756C0A9639C8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "YAKATAN, GERALD Y"}, {"name": "organizations", "value": "AVANIR PHARMACEUTICALS"}, {"name": "subject", "value": "NEURODEX (DRUG)"}, {"name": "subject", "value": "CRYING"}, {"name": "subject", "value": "BRAIN"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PBA (PSEUDOBULBAR AFFECT)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2005-05-09T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 2, "offset": 0, "time": 23}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}